Imidomics

Developer of medicines for the treatment of immune-mediated inflammatory diseases

placeSan Francisco, California, United States calendar_todayFounded 2015 groups25 employees language imidomics.com

Social engagement

Social engagement: 1.6K social following, 2 posts in the last 12 months — below the industry typical range.

Investor mix

7 investors on record; lead investors include DNS Capital, Evotec.

Investor typeCountShare
Venture capital114%
Private equity229%
Other / undisclosed457%

Recent activity

30 Jul 2025
Partnership
Formation Bio
29 Jul 2025
Partnership
Formation Bio
Coming soon